Florian I. Schmidt Lab

SARS-CoV-2 Neutralizing Single Domain Antibodies (VHHs)

Project details

In a joint project with the respective Core Facility at the University of Bonn, we have generated SARS-CoV-2 neutralizing single domain antibodies (VHHs) to study mechanistic aspects of virus fusion and to develop novel antiviral biologics. While we continue to investigate basic research aspects of SARS-CoV-2 infection and fusion with the VHH technology, the clinical development of antiviral SARS-CoV-2 single domain antibodies was pursued by the spin-out company DiosCURE Therapeutics SE of the University of Bonn.

‍

Project-related publications

Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape

Koenig PA, Das H, Liu H, Kümmerer BM, Gohr FN, Jenster LM, Schiffelers LDJ, Tesfamariam YM, Uchima M, Wuerth JD, Gatterdam K, Ruetalo N, Christensen MH, Fandrey CI, Normann S, Tödtmann JMP, Pritzl S, Hanke L, Boos J, Yuan M, Zhu X, Schmid-Burgk JL, Kato H, Schindler M, Wilson IA, Geyer M, Ludwig KU, Hällberg BM, Wu NC, Schmidt FI.